Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study

A randomized multicenter 96-week study of an elsulfavirine (ESV),  non-nucleoside reverse transcriptase inhibitor (NNRTI) of novel  generation, in combination with 2 nucleoside/ nucleotide reverse  transcriptase inhibitors (NRTIs) was conducted in naive HIV adult  patients, divided by 2 parts: 1) pa...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Kravchenko, E. A. Orlova-Morozova, T. E. Shimonova, O. A. Kozyrev, F. I. Nagimova, N. G. Zaharova, E. S. Ivanova, U. A. Kuimova, A. A. Popova, O. E. Chernova, O. S. Tonkih, D. A. Gusev, A. A. Yakovlev, V. V. Pokrovsky, V. V. Bychko, N. V. Vostokova
Format: Article
Language:Russian
Published: Journal Infectology 2018-07-01
Series:Журнал инфектологии
Subjects:
hiv-infection
art
nnrti
elsulfavirine
Online Access:https://journal.niidi.ru/jofin/article/view/731
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://journal.niidi.ru/jofin/article/view/731

Similar Items